1-11 of 11
Teiko Sumiyoshi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrative Analysis of the Tumor and Microenvironment to Model the Molecular Heterogeneity Underlying the Response to Cevostamab in Relapsed/Refractory Multiple Myeloma

Habib Hamidi, Rin Nakamura, Sumi Roy, Kamalakannan Rajasekaran, Giovanni Diaz, Cedric Dos Santos, Teiko Sumiyoshi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3305.
https://doi.org/10.1182/blood-2023-174075
Published: 2023
Journal Articles

Novel Transcriptomics Based Stratification Approach Using the Commpass Dataset Reveals Mechanistic Insights into Current and Upcoming MM Therapies

Habib Hamidi, Teiko Sumiyoshi, Cedric E. Dos Santos, Samuel Tracy, Hearn J. Cho, Stephanie Hilz, Vivek S. Chopra
Journal: Blood
Blood (2022) 140 (Supplement 1): 7208–7210.
https://doi.org/10.1182/blood-2022-163868
Published: 2022
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 2755.
https://doi.org/10.1182/blood-2021-147418
Published: 2021
Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D Cohen, Amrita Y. Krishnan, Rafael Fonseca, Andrew Spencer, Jesús G. Berdeja, Alexander Lesokhin, Peter A Forsberg, Jacob P. Laubach, Luciano J. Costa, Paula Rodriguez-Otero, Rayan Kaedbey, Joshua Richter, Maria-Victoria Mateos, Sheeba K Thomas, Chihunt Wong, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 157.
https://doi.org/10.1182/blood-2021-147983
Published: 2021
Journal Articles

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Rin Nakamura, Sean Lear, Deanna Wilson, Hartmut Koeppen, Anjali Vaze, Suzanne Trudel, MD MSC, FRCPC, Andrew Spencer, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Adam D. Cohen, MD, Bernard M Fine, Mengsong Li, James Cooper, Teiko Sumiyoshi
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136980
Published: 2020
Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136985
Published: 2020
Journal Articles

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Elisabeth A Lasater, PhD, An D Do, Luciana Burton, Yijin Li, Erin Williams, Jason Oeh, Luciana Molinero, Elicia Penuel, Deepak Sampath, Monique Dail, Marcia Belvin, Teiko Sumiyoshi, Elizabeth A Punnoose, Jeffrey Venstrom, Aparna Raval
Journal: Blood
Blood (2018) 132 (Supplement 1): 1118.
https://doi.org/10.1182/blood-2018-99-116405
Published: 2018
Journal Articles

Anti-FcRH5/CD3 T Cell Dependent Bispecific Antibody (TDB) for the Treatment of Multiple Myeloma

Ji Li, Nicola Stagg, Jennifer Johnston, Michael Harris, Sam Menzies, Danielle DiCara, Vanessa Clark, Ryan Cook, Dionysos Slaga, Rin Nakamura, McCarty Luke, Siddharth Sukumaran, Elizabeth Luis, Zhengmao Ye, Teiko Sumiyoshi, Dimitry Danilenko, Genee Lee, Klara Totpal, Diego Ellerman, Isidro Hötzel, John James, Teemu T Junttila
Journal: Blood
Blood (2016) 128 (22): 4475.
https://doi.org/10.1182/blood.V128.22.4475.4475
Published: 2016
Journal Articles

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Mahesh Yadav, Cherie Green, Connie Ma, Alberto Robert, Andrew Glibicky, Rin Nakamura, Teiko Sumiyoshi, Ray Meng, Yu-Waye Chu, Jenny Wu, John Byon, Joseph Woodard, Joanne Adamkewicz, Jane Grogan, Jeffrey M. Venstrom
Journal: Blood
Blood (2016) 128 (22): 2102.
https://doi.org/10.1182/blood.V128.22.2102.2102
Published: 2016
Journal Articles

Optimization of the Sleeping Beauty Transposon System to Achieve Stable Transgene Expression in Human CD34+ Hematopoietic Progenitor Cells

Teiko Sumiyoshi, MS, Roger P Hollis, PhD, Nathalia Holt, MS, Donald B. Kohn, MD
Journal: Blood
Blood (2008) 112 (11): 3527.
https://doi.org/10.1182/blood.V112.11.3527.3527
Published: 2008